THE APEX TIMES
State Street’s Financial Select Sector SPDR (XLF) reduced exposure to Berkshire Hathaway and JPMorgan Chase in the latest disclosed trades, with no new buys across its portfolio.
State Street’s Financial Select Sector SPDR, or XLF, reported a net reduction in positions on Friday, cutting holdings tied to Berkshire Hathaway and JPMorgan Chase while making no purchases elsewhere in the fund’s portfolio activity.
According to the trade summary published in a market update, XLF, a roughly $53.58 billion exchange-traded fund, sold a total of $370.1 million across 76 positions during the trading day.
The same disclosure indicated that Berkshire Hathaway and JPMorgan Chase were among the names trimmed by the fund. JPMorgan’s shares are listed under the NYSE ticker JPM.
In that activity window, the fund reported sales across its positions but disclosed no buys, suggesting the move was consistent with trimming and turnover rather than adding new exposure in the financial sector ETF’s basket.
For investors tracking the financial space through XLF, these types of trade prints are usually read as indications of short-term portfolio rebalancing, liquidity management, or index-tracking adjustments. Because exchange-traded funds place trades throughout the day rather than waiting for month-end rollups, single-day activity can look uneven even when longer-term allocations remain stable.
Still, a key detail is what the posting does not provide. The market update does not break out how much XLF sold specifically in Berkshire versus JPMorgan, nor does it explain whether the changes were driven by underlying index methodology, corporate actions, risk controls, or internal portfolio constraints.
Beyond the individual stock moves, XLF’s scale matters. With a fund size of about $53.58 billion referenced in the same update, even partial reductions in large, liquid holdings can translate into meaningful order flow, though the disclosure here does not quantify the portion of total market volume attributable to XLF.
What to watch next is whether subsequent reporting shows continued selling pressure in large bank and insurance names, or whether XLF later reverses course with buys after the no-buy day reported for Friday. Another point for market observers will be whether the fund’s next disclosed activity shows similar breadth, meaning trimming across many positions, or a narrower set of adjustments concentrated in specific financial subsectors.
The latest Wall Street adjustment to Amazon’s AMZN shares points to continuing optimism about AWS as analysts weigh how much profitability the cloud business can sustain.
The firm increased its view on Apple despite a post-earnings reaction tied to margin pressure and softer services momentum.
Palantir reported results that beat third-quarter expectations and showed continued growth momentum, but analysts said valuation concerns are still a factor.
A market-focused preview ahead of AMD results argues the stock’s AI-driven momentum depends on whether the company can post an earnings surprise, with analysts tracking revenue expectations near $13 billion.
The company’s reported mix of stock and bond financing is drawing attention to how major software and cloud providers fund data-center and AI-related demand.
The company reported results that topped expectations, but investors focused on a weaker view for the period ahead as rising memory costs weighed on sentiment.
Pfizer said its third-quarter net income totaled $3, according to a market earnings recap published by Yahoo Finance on Tuesday. The post did not detail revenue, guidance, or segment performance.
A Truist note argues Palantir is positioned to benefit from rising demand for AI-enabled software, pointing to an improving revenue trajectory after the company reported its latest results.
A report says Nvidia has instructed some data-center partners to structure sales so at least 51% of services revenue comes from outside China, a move that highlights how export and geopolitical risk is shaping AI hardware channels.
The stock rose about 12% over the past month, supported by FDA approvals and progress in areas including multiple myeloma and infant vaccination data, as broader indexes moved the other direction.